Skip to content 
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. more
| Time Frame | BMY | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -0.2% | 1.51% | -1.5% |
| 1-Month Return | 12.03% | 1.46% | 0.6% |
| 3-Month Return | 29.76% | 3.94% | 2.43% |
| 6-Month Return | 26.04% | 16.03% | 6.01% |
| 1-Year Return | 11.59% | 9.1% | 11.48% |
| 3-Year Return | -14.58% | 19.46% | 67.52% |
| 5-Year Return | 0.25% | 35.29% | 73.75% |
| 10-Year Return | -4.97% | 137.42% | 254.46% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 46.38B | 46.16B | 45.01B | 48.30B | 48.19B | [{"date":"2021-12-31","value":96.04,"profit":true},{"date":"2022-12-31","value":95.57,"profit":true},{"date":"2023-12-31","value":93.18,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":99.78,"profit":true}] |
| Cost of Revenue | 19.62B | 19.67B | 19.65B | 20.87B | 15.59B | [{"date":"2021-12-31","value":94.04,"profit":true},{"date":"2022-12-31","value":94.25,"profit":true},{"date":"2023-12-31","value":94.16,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":74.72,"profit":true}] |
| Gross Profit | 26.76B | 26.49B | 25.36B | 27.43B | 32.60B | [{"date":"2021-12-31","value":82.08,"profit":true},{"date":"2022-12-31","value":81.25,"profit":true},{"date":"2023-12-31","value":77.78,"profit":true},{"date":"2024-12-31","value":84.14,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Margin | 57.69% | 57.39% | 56.34% | 56.80% | 67.65% | [{"date":"2021-12-31","value":85.29,"profit":true},{"date":"2022-12-31","value":84.83,"profit":true},{"date":"2023-12-31","value":83.29,"profit":true},{"date":"2024-12-31","value":83.96,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Operating Expenses | 17.22B | 17.22B | 16.89B | 17.77B | 19.91B | [{"date":"2021-12-31","value":86.51,"profit":true},{"date":"2022-12-31","value":86.5,"profit":true},{"date":"2023-12-31","value":84.82,"profit":true},{"date":"2024-12-31","value":89.29,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Operating Income | 9.54B | 9.27B | 8.47B | 9.66B | 12.70B | [{"date":"2021-12-31","value":75.14,"profit":true},{"date":"2022-12-31","value":73.02,"profit":true},{"date":"2023-12-31","value":66.73,"profit":true},{"date":"2024-12-31","value":76.07,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Total Non-Operating Income/Expense | (2.78B) | (2.79B) | (1.18B) | (19.98B) | (5.26B) | [{"date":"2021-12-31","value":-277600000000,"profit":false},{"date":"2022-12-31","value":-279000000000,"profit":false},{"date":"2023-12-31","value":-117600000000,"profit":false},{"date":"2024-12-31","value":-1998400000000,"profit":false},{"date":"2025-12-31","value":-525900000000,"profit":false}] |
| Pre-Tax Income | 8.10B | 7.71B | 8.44B | (8.38B) | 9.33B | [{"date":"2021-12-31","value":86.81,"profit":true},{"date":"2022-12-31","value":82.69,"profit":true},{"date":"2023-12-31","value":90.48,"profit":true},{"date":"2024-12-31","value":-89.83,"profit":false},{"date":"2025-12-31","value":100,"profit":true}] |
| Income Taxes | 1.08B | 1.37B | 400.00M | 554.00M | 2.27B | [{"date":"2021-12-31","value":47.71,"profit":true},{"date":"2022-12-31","value":60.21,"profit":true},{"date":"2023-12-31","value":17.61,"profit":true},{"date":"2024-12-31","value":24.38,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Income After Taxes | 7.01B | 6.34B | 8.04B | (8.93B) | 7.06B | [{"date":"2021-12-31","value":87.24,"profit":true},{"date":"2022-12-31","value":78.92,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-111.11,"profit":false},{"date":"2025-12-31","value":87.76,"profit":true}] |
| Income From Continuous Operations | 7.01B | 6.34B | 8.30B | (8.93B) | 7.05B | [{"date":"2021-12-31","value":84.48,"profit":true},{"date":"2022-12-31","value":76.42,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-107.59,"profit":false},{"date":"2025-12-31","value":84.97,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | 6.99B | 6.33B | 8.03B | (8.95B) | 7.05B | [{"date":"2021-12-31","value":87.15,"profit":true},{"date":"2022-12-31","value":78.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-111.5,"profit":false},{"date":"2025-12-31","value":87.89,"profit":true}] |
| EPS (Diluted) | 7.50 | 7.80 | 7.39 | 1.14 | 6.15 | [{"date":"2021-12-31","value":96.15,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.74,"profit":true},{"date":"2024-12-31","value":14.62,"profit":true},{"date":"2025-12-31","value":78.85,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| BMY | |
|---|---|
| Cash Ratio | -4.72 |
| Current Ratio | -4.72 |
| Quick Ratio | -3.53 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| BMY | |
|---|---|
| ROA (LTM) | 10.29% |
| ROE (LTM) | 40.44% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| BMY | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | -4.23 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 5.23 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| BMY | |
|---|---|
| Trailing PE | 17.54 |
| Forward PE | 9.96 |
| P/S (TTM) | 2.55 |
| P/B | 6.70 |
| Price/FCF | 10 |
| EV/R | 3.32 |
| EV/Ebitda | 10.52 |
| PEG | 2.26 |
Bristol-Myers Squibb Company (BMY) share price today is $60.35
Yes, Indians can buy shares of Bristol-Myers Squibb Company (BMY) on Vested. To buy
Yes, you can purchase fractional shares of Bristol-Myers Squibb Company (BMY) via the Vested app. You can start investing in Bristol-Myers Squibb Company (BMY) with a minimum investment of $1.
You can invest in shares of Bristol-Myers Squibb Company (BMY) via Vested in three simple steps:
The 52-week high price of Bristol-Myers Squibb Company (BMY) is $62.05. The 52-week low price of Bristol-Myers Squibb Company (BMY) is $41.88.
The price-to-earnings (P/E) ratio of Bristol-Myers Squibb Company (BMY) is
The price-to-book (P/B) ratio of Bristol-Myers Squibb Company (BMY) is 6.70
The dividend yield of Bristol-Myers Squibb Company (BMY) is 4.16%
The market capitalization of Bristol-Myers Squibb Company (BMY) is $123.70B
The stock symbol (or ticker) of Bristol-Myers Squibb Company is BMY
Consider the share price of Bristol-Myers Squibb Company as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Bristol-Myers Squibb Company has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Bristol-Myers Squibb Company shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Bristol-Myers Squibb Company stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Bristol-Myers Squibb Company and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Bristol-Myers Squibb Company stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
